Trial · NCT04426578
Role of Perhexiline in Hypertrophic Cardiomyopathy
NCT04426578, Phase 2, Unknown, Flinders University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Role of Perhexiline in Hypertrophic Cardiomyopathy. Trials, record NCT04426578. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04426578
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Role of Perhexiline in Hypertrophic Cardiomyopathy
- NCT number
- NCT04426578
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Flinders University
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Perhexiline, Placebo
- First posted
- 2020-06-11
- Last updated
- 2021-03-11
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Left Ventricular Hypertrophy (LVH) | 12 months post baseline | Change in LVH (septal thickness) in symptomatic at 12 months following perhexiline therapy in HCM patients assessed by CMR |
| Secondary | Change in Left Ventricular (LV) mass | 12 months post baseline | Change in left ventricular mass in symptomatic at 12 months following perhexiline therapy in HCM patients assessed by CMR |
| Secondary | Change in oxygen-sensitive Cardiac Magnetic Resonance | 12 months post baseline | Change in oxygen-sensitive CMR in symptomatic at 12 months following perhexiline therapy in HCM patients |
| Secondary | Change in left ventricular diastolic function | 12 months post baseline | Change in left ventricular diastolic function at 12 months following perhexiline therapy in HCM patients assessed by echocardiography |
| Secondary | New York Heart Association (NYHA) functional classification | 12 months post baseline | Change in NYHA classification of Class I, II, III and IV at 12 months following perhexiline therapy in HCM patients |
| Secondary | Canadian Cardiovascular Society (CCS) functional class | 12 months post baseline | Change in CCS functional classification of Grade I, II, III and IV at 12 months following perhexiline therapy in HCM patients |
| Secondary | Quality of life assessment | 12 months post baseline | Change in physical activity domain score of Short Form 36 Health Survey Questionnaire (SF36) at 12 months following perhexiline therapy in HCM patients |
| Secondary | Major adverse event on heart failure related hospitalisations | Monitored over the 12 months period | HCM patients admitted with heart failure during the study period |
| Secondary | Major adverse event on arrhythmic events | Monitored over the 12 months period | HCM patients admitted with arrhythmic events during the study period |
| Secondary | Major adverse event on abnormal liver function test | Liver function tests at baseline, 1 month, 6 months and 12 months | HCM patients with abnormal liver function tests during the study period |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04426578
GET https://conductscience.org/api/trials/v1/NCT04426578/registered